Adjunctive corticosteroid therapy for inpatients with Mycoplasma pneumoniae pneumonia
Abstract Background There is conflicting evidence regarding the benefit of adjunctive corticosteroid therapy in patients with Mycoplasma pneumoniae pneumonia. We hypothesised that corticosteroid therapy could reduce mortality and length of stay (LOS) in such patients. Methods Adult patients with M....
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-12-01
|
Series: | BMC Pulmonary Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12890-017-0566-4 |
id |
doaj-7143a72d1e1348668572dcd4e5538532 |
---|---|
record_format |
Article |
spelling |
doaj-7143a72d1e1348668572dcd4e55385322020-11-24T21:08:47ZengBMCBMC Pulmonary Medicine1471-24662017-12-0117111010.1186/s12890-017-0566-4Adjunctive corticosteroid therapy for inpatients with Mycoplasma pneumoniae pneumoniaMasato Tashiro0Kiyohide Fushimi1Kei Kawano2Takahiro Takazono3Tomomi Saijo4Kazuko Yamamoto5Shintaro Kurihara6Yoshifumi Imamura7Taiga Miyazaki8Katsunori Yanagihara9Hiroshi Mukae10Koichi Izumikawa11Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical SciencesDepartment of Health Policy and Informatics, Graduate School of Medicine, Tokyo Medical and Dental UniversityNagasaki University Infection Control and Education Centre, Nagasaki University HospitalDepartment of Infectious Diseases, Nagasaki University Graduate School of Biomedical SciencesSecond Department of Internal Medicine, Nagasaki University HospitalSecond Department of Internal Medicine, Nagasaki University HospitalNagasaki University Infection Control and Education Centre, Nagasaki University HospitalSecond Department of Internal Medicine, Nagasaki University HospitalDepartment of Infectious Diseases, Nagasaki University Graduate School of Biomedical SciencesDepartment of Laboratory Medicine, Nagasaki University HospitalSecond Department of Internal Medicine, Nagasaki University HospitalDepartment of Infectious Diseases, Nagasaki University Graduate School of Biomedical SciencesAbstract Background There is conflicting evidence regarding the benefit of adjunctive corticosteroid therapy in patients with Mycoplasma pneumoniae pneumonia. We hypothesised that corticosteroid therapy could reduce mortality and length of stay (LOS) in such patients. Methods Adult patients with M. pneumoniae pneumonia from January 2010 to December 2013 were identified from the Japanese Diagnosis Procedure Combination inpatient database. The effects of low-dose and high-dose corticosteroid therapies on mortality, LOS, drug costs and hyperglycaemia requiring insulin treatment were evaluated using propensity score analyses. Results Eligible patients (n = 2228) from 630 hospitals were divided into no-corticosteroid (n = 1829), low-dose corticosteroid (n = 267) and high-dose corticosteroid (n = 132) groups. The propensity score-matched pairs were generated from no-corticoid and low-dose corticoid groups (251 pairs), or no-corticoid and high-dose corticosteroid groups (120 pairs). Adjunctive corticosteroid therapy did not decrease 30-day mortality. In addition, both low-dose and high-dose corticosteroid therapies were associated with increases in LOS. Furthermore, hyperglycaemia requiring insulin treatment and drug cost increased with corticosteroid use. Conclusions Adjunctive treatment with low-dose or high-dose corticosteroids may not be beneficial in M. pneumoniae pneumonia.http://link.springer.com/article/10.1186/s12890-017-0566-4Mycoplasma pneumoniaePneumoniaCorticosteroid |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Masato Tashiro Kiyohide Fushimi Kei Kawano Takahiro Takazono Tomomi Saijo Kazuko Yamamoto Shintaro Kurihara Yoshifumi Imamura Taiga Miyazaki Katsunori Yanagihara Hiroshi Mukae Koichi Izumikawa |
spellingShingle |
Masato Tashiro Kiyohide Fushimi Kei Kawano Takahiro Takazono Tomomi Saijo Kazuko Yamamoto Shintaro Kurihara Yoshifumi Imamura Taiga Miyazaki Katsunori Yanagihara Hiroshi Mukae Koichi Izumikawa Adjunctive corticosteroid therapy for inpatients with Mycoplasma pneumoniae pneumonia BMC Pulmonary Medicine Mycoplasma pneumoniae Pneumonia Corticosteroid |
author_facet |
Masato Tashiro Kiyohide Fushimi Kei Kawano Takahiro Takazono Tomomi Saijo Kazuko Yamamoto Shintaro Kurihara Yoshifumi Imamura Taiga Miyazaki Katsunori Yanagihara Hiroshi Mukae Koichi Izumikawa |
author_sort |
Masato Tashiro |
title |
Adjunctive corticosteroid therapy for inpatients with Mycoplasma pneumoniae pneumonia |
title_short |
Adjunctive corticosteroid therapy for inpatients with Mycoplasma pneumoniae pneumonia |
title_full |
Adjunctive corticosteroid therapy for inpatients with Mycoplasma pneumoniae pneumonia |
title_fullStr |
Adjunctive corticosteroid therapy for inpatients with Mycoplasma pneumoniae pneumonia |
title_full_unstemmed |
Adjunctive corticosteroid therapy for inpatients with Mycoplasma pneumoniae pneumonia |
title_sort |
adjunctive corticosteroid therapy for inpatients with mycoplasma pneumoniae pneumonia |
publisher |
BMC |
series |
BMC Pulmonary Medicine |
issn |
1471-2466 |
publishDate |
2017-12-01 |
description |
Abstract Background There is conflicting evidence regarding the benefit of adjunctive corticosteroid therapy in patients with Mycoplasma pneumoniae pneumonia. We hypothesised that corticosteroid therapy could reduce mortality and length of stay (LOS) in such patients. Methods Adult patients with M. pneumoniae pneumonia from January 2010 to December 2013 were identified from the Japanese Diagnosis Procedure Combination inpatient database. The effects of low-dose and high-dose corticosteroid therapies on mortality, LOS, drug costs and hyperglycaemia requiring insulin treatment were evaluated using propensity score analyses. Results Eligible patients (n = 2228) from 630 hospitals were divided into no-corticosteroid (n = 1829), low-dose corticosteroid (n = 267) and high-dose corticosteroid (n = 132) groups. The propensity score-matched pairs were generated from no-corticoid and low-dose corticoid groups (251 pairs), or no-corticoid and high-dose corticosteroid groups (120 pairs). Adjunctive corticosteroid therapy did not decrease 30-day mortality. In addition, both low-dose and high-dose corticosteroid therapies were associated with increases in LOS. Furthermore, hyperglycaemia requiring insulin treatment and drug cost increased with corticosteroid use. Conclusions Adjunctive treatment with low-dose or high-dose corticosteroids may not be beneficial in M. pneumoniae pneumonia. |
topic |
Mycoplasma pneumoniae Pneumonia Corticosteroid |
url |
http://link.springer.com/article/10.1186/s12890-017-0566-4 |
work_keys_str_mv |
AT masatotashiro adjunctivecorticosteroidtherapyforinpatientswithmycoplasmapneumoniaepneumonia AT kiyohidefushimi adjunctivecorticosteroidtherapyforinpatientswithmycoplasmapneumoniaepneumonia AT keikawano adjunctivecorticosteroidtherapyforinpatientswithmycoplasmapneumoniaepneumonia AT takahirotakazono adjunctivecorticosteroidtherapyforinpatientswithmycoplasmapneumoniaepneumonia AT tomomisaijo adjunctivecorticosteroidtherapyforinpatientswithmycoplasmapneumoniaepneumonia AT kazukoyamamoto adjunctivecorticosteroidtherapyforinpatientswithmycoplasmapneumoniaepneumonia AT shintarokurihara adjunctivecorticosteroidtherapyforinpatientswithmycoplasmapneumoniaepneumonia AT yoshifumiimamura adjunctivecorticosteroidtherapyforinpatientswithmycoplasmapneumoniaepneumonia AT taigamiyazaki adjunctivecorticosteroidtherapyforinpatientswithmycoplasmapneumoniaepneumonia AT katsunoriyanagihara adjunctivecorticosteroidtherapyforinpatientswithmycoplasmapneumoniaepneumonia AT hiroshimukae adjunctivecorticosteroidtherapyforinpatientswithmycoplasmapneumoniaepneumonia AT koichiizumikawa adjunctivecorticosteroidtherapyforinpatientswithmycoplasmapneumoniaepneumonia |
_version_ |
1716759385406963712 |